Author

S. R. Stauffer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Assay:ChIP-seq· 1 Approach:deep learning· 1 Assay:organoid / primary culture· 1 Approach:statistical model· 1

Frequent Co-Authors

A. A. Chakraborty· 1 shared A. A. Hakimi· 1 shared A. Kashyap· 1 shared A. Lauko· 1 shared A. P. Patel· 1 shared C. G. Hubert· 1 shared C. J. Weight· 1 shared C. M. Goins· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Chakraborty

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The SLC1A1/EAAT3 Dicarboxylic Amino Acid Transporter is an Epigenetically Dysregulated Nutrient Carrier that Sustains Oncogenic Metabolic Programs

T. M. Grubb, J. Khatun, S. Matar, F. Ghandour, N. Dubasik, C. Salem, D. A. Orlando, M. G. Guenther, S. R. Martinez, P. Koochaki, J. A. Coker, C. Tang, E. Reznik, R. R. Kotecha, A. A. Hakimi, , A. A. Chakraborty

This study identifies SLC1A1/EAAT3 as an oncogenic transporter in ccRCC driven by H3K27ac, showing its role in sustaining metabolic programs and its potential as a therapeutic target.

bioRxiv · Sep 4, 2023 · PreprintCancer Biology

WDR5 represents a therapeutically exploitable target for cancer stem cells in glioblastoma

K. Mitchell, S. Shakya, S. Arora, S. A. Sprowls, D. J. Silver, C. M. Goins, L. Wallace, G. Roversi, R. Schafer, K. Kay, T. E. Miller, A. Lauko, A. Kashyap, J. D. Kass, E. E. Mulkearns-Hubert, , J. D. Lathia

This study identifies WDR5 as an essential epigenetic regulator in therapy-resistant glioblastoma cancer stem cells and shows that WDR5 inhibitors disrupt CSC maintenance and tumor growth.

bioRxiv · Sep 20, 2021Cancer Biology